Event Sponsors

HistoRx has signed its first diagnostic licensing agreement with Genoptix, the premier U.S. oncology clinical laboratory, for their use in offering several diagnostic assays. These assays are expected to launch in 2010, making AQUA technology available to the general public for the first time.

AQUA software for fluorescent image analysis is now available on Aperio's new ScanScope FL, a multi-slide fluorescence scanning system designed to meet the growing demand for multiplexing with fluorescent biomarkers and quantitative analysis.

By using real-time feedback information, KineMed's innovative approaches can guide, filter, and optimize drug development. A portfolio of drugs can therefore be advanced more effectively and with significantly greater chances of success.
KineMed's goal is to use its translational medicine platform to resolve two major challenges in pharmaceutical R&D: Translation and Personalization.
KineMed provides a deep, real-time view into drug actions in living systems — both animal and human — and bridges the gap between the laboratory and the clinic. It enables translation of scientific discoveries into effective medicines.
This real-time view into living systems also enables KineMed to identify otherwise unappreciated heterogeneity among patients and within diseases and to relate these variations to drug effects. This can help delineate the characteristics of responders and non-responders earlier in clinical development. This ability to discern such differences earlier allows better patient stratification during development and increases the chances of success. By increasing expected signal-to-noise, it also can allow smaller studies to reach significant outcomes. KineMed's Personalized Medicine platform results in testing and using the right drugs in the right patients.

DDW examines the advances in new science and technology with a view to the commercial implications of implementing those advances and whether they can truly bring benefits to the industry as a whole and, more importantly, the discovery and development of new therapeutics.

DDW is distinguishable in that it reaches out to a global audience at both bench and boardroom level allowing them to understand the new technologies and the impact they can have on their particular segments of the business. Scientist and CEO alike can profit from the uncomplicated style of the editorial and, furthermore, gain a wealth of information on a diverse range of life science topics. In our articles, we challenge the industry to look at new ways of overcoming discovery bottlenecks, embrace new technologies and build next generation technology platforms.

DDW aims to help the industry survive the 'revolution' as a 'must read' for all those involved in this dynamic sector where time is of the essence and knowledge is power.